|
|
|
|
|
HONG KONG, Dec 23, 2022 - (ACN Newswire) - Shares of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX"), under the stock code 6929.
 | | Mr. Teddy Chien, Chairman Emeritus and Founder (right) and Mr. David Chien, Chairman, Executive Director, Chief Executive Officer (left), together strike the ceremonial gong, marking the Group's listing on the Main Board of HKEX |
 | | Mr. David Chien, Chairman, Executive Director, Chief Executive Officer (right) presents a souvenir to HKEX |
 | | OrbusNeich makes a generous donation of HK$3,000,000 to HKEX Foundation to secure the auspicious stock code number "6929". Mr. David Chien, Chairman, Executive Director, Chief Executive Officer (right) presents the cheque to HKEX |
 | | (From left to right): John Chow,Executive Director and Head of Business Development; Jason Chen, Executive Director, Chief Financial Officer and Company Secretary; Gloria Tam, Independent Non-executive Director; Denise Lau, Executive Director and Chief Operating Officer; Teddy Chien, Chairman Emeritus and Founder; David Chien, Chairman, Executive Director and Chief Executive Officer; George Lau, Independent Non-executive Director; Angus Chan, Independent Non-executive Director |
About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells products to over 70 countries and regions worldwide, and it is also the only PCI balloon manufacturer headquartered in China that ranked among the top 6 players in all major overseas PCI balloon markets including Japan (Ranked No. 2), Europe (Ranked No. 4), and the U.S. (Ranked No. 6) in terms of sales volume of PCI balloons in 2021 in accordance with the CIC Report. In addition, in terms of sales volume of PTA balloons in 2021, it ranked No. 3 in Japan and No. 4 in the U.S., respectively. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease areas. OrbusNeich owns more than 180 granted patents globally. Its in-house R&D team has over twenty years of product development experience and has developed proprietary, world leading technologies.
For more details, please visit the Group's official website: https://orbusneich.com/
Topic: Press release summary
Source: OrbusNeich Medical Group Holdings Limited
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| OrbusNeich Medical Group Holdings Limited |
| Mar 7, 2024 17:20 HKT/SGT |
|
OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share |
| Nov 27, 2023 09:00 HKT/SGT |
|
OrbusNeich Acquires 84% Stake in Indonesian Distributor PT Revass for Approximately US$15 Million |
| Nov 23, 2023 09:15 HKT/SGT |
|
OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG |
| Aug 17, 2023 17:52 HKT/SGT |
|
OrbusNeich FY2023 Interim Net Profit Triples to US$25.2 Million, Total Revenue Increases by 18.2% to US$81.4 Million |
| May 8, 2023 17:58 HKT/SGT |
|
OrbusNeich Kicks Off Clinical Study of Scoreflex TRIO, Completing China's First PCI Intervention Procedure with High-Pressure, Three-wire Scoring Balloon Dilatation Catheter |
| Mar 28, 2023 17:28 HKT/SGT |
|
OrbusNeich Plans to Set up Its Largest R&D and Production Base in Fuchun Bay New Town, Hangzhou, the PRC |
| Mar 8, 2023 18:00 HKT/SGT |
|
OrbusNeich Announces First Annual Results After Listing, Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million |
| Dec 13, 2022 10:10 HKT/SGT |
|
Major Global Medical Device Manufacturer OrbusNeich Medical Group Announces Details of Proposed Listing on the Main Board of HKEX |
| More news >> |
 |
|
|
|
